Relation of plasma PCSK9 levels to lipoprotein subfractions in patients with stable coronary artery disease

Lipids in Health and Disease

Volumn 13, Issue 1, 2014, Pages

  Xu, Rui Xia ^a   Li, Sha ^a   Zhang, Yan ^a   Li, Xiao Lin ^a   Guo, Yuan Lin ^a   Zhu, Cheng Gang ^a   Li, Jian Jun ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

Coronary artery disease; HDL subfractions; LDL subfractions; Proprotein convertase subtilisin kexin type 9

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERMEDIATE HIGH DENSITY LIPOPROTEIN; INTERMEDIATE LOW DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SERINE PROTEINASE; SMALL HIGH DENSITY LIPOPROTEIN; SMALL LOW DENSITY LIPOPROTEIN CHOLESTEROL; UNCLASSIFIED DRUG; PCSK9 PROTEIN, HUMAN;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; ENZYME BLOOD LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARTICLE SIZE; SEX DIFFERENCE; AGED; BLOOD; ENZYMOLOGY; MIDDLE AGED; SEXUAL DEVELOPMENT;

AGED; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES; SEX CHARACTERISTICS;

EID: 84976897420     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-13-188     Document Type: Article

References (45)

1. Li JJ, Li YS, Fang CH, Hui RT, Yang YJ, Cheng JL, Gao RL: Effects of simvastatin within two weeks on anti-inflammatory cytokine interleukin 10 in patients with unstable angina. Heart. 2006, 92 (4): 529-530.
2. Cariou B, Le May C, Costet P: Clinical aspects of PCSK9. Atherosclerosis. 2011, 216 (2): 258-265.
3. Lambert G, Sjouke B, Choque B, Kastelein JJ, Hovingh GK: The PCSK9 decade. J Lipid Res. 2012, 53 (12): 2515-2524.
4. Seidah NG, Prat A: The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov. 2012, 11 (5): 367-383.
5. Schmidt RJ, Zhang Y, Zhao Y, Qian YW, Wang H, Lin A, Ehsani ME, Yu X, Wang G, Singh J, Su EW, Li S, Konrad RJ, Cao G: A novel splicing variant of proprotein convertase subtilisin/kexin type 9. DNA Cell Biol. 2008, 27 (4): 183-189.
6. Seidah NG, Benjannet S, Wickham L, Marcinkiewicz J, Jasmin SB, Stifani S, Basak A, Prat A, Chretien M: The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci U S A. 2003, 100 (3): 928-933.
7. Lagace TA, Curtis DE, Garuti R, McNutt MC, Park SW, Prather HB, Anderson NN, Ho YK, Hammer RE, Horton JD: Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest. 2006, 116 (11): 2995-3005.
8. Horton JD, Cohen JC, Hobbs HH: PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res. 2009, 50: S172-S177.
9. Seidah NG: PCSK9 as a therapeutic target of dyslipidemia. Expert Opin Ther Targets. 2009, 13 (1): 19-28.
10. Baass A, Dubuc G, Tremblay M, Delvin EE, O'Loughlin J, Levy E, Davignon J, Lambert M: Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents. Clin Chem. 2009, 55 (9): 1637-1645.
11. Galeano NF, Al-Haideri M, Keyserman F, Rumsey SC, Deckelbaum RJ: Small dense low density lipoprotein has increased affinity for LDL receptor-independent cell surface binding sites: a potential mechanism for increased atherogenicity. J Lipid Res. 1998, 39 (6): 1263-1273.
12. Folse HJ, Goswami D, Rengarajan B, Budoff M, Kahn R: Clinical- and cost-effectiveness of LDL particle-guided statin therapy: A simulation study. Atherosclerosis. 2014, 236 (1): 154-161.
13. Ip S, Lichtenstein AH, Chung M, Lau J, Balk EM: Systematic review: association of low-density lipoprotein subfractions with cardiovascular outcomes. Ann Intern Med. 2009, 150 (7): 474-484.
14. Christogiannis LG, Kostapanos MS, Tellis CC, Milionis HJ, Tselepis AD, Elisaf MS: Distinct effects of fixed combinations of valsartan with either amlodipine or hydrochlorothiazide on lipoprotein subfraction profile in patients with hypertension. J Hum Hypertens. 2013, 27 (1): 44-50.
15. Banuls C, Bellod L, Jover A, Martinez-Triguero ML, Victor VM, Rocha M, Hernandez-Mijares A: Comparability of two different polyacrylamide gel electrophoresis methods for the classification of LDL pattern type. Clin Chim Acta. 2012, 413 (1-2): 251-257.
16. Marais AD, Kim JB, Wasserman SM, Lambert G: PCSK9 inhibition in LDL cholesterol reduction: Genetics and therapeutic implications of very low plasma lipoprotein levels. Pharmacol Ther. 2014, [Epub ahead of print]
17. Abifadel M, Varret M, Rabes JP, Allard D, Ouguerram K, Devillers M, Cruaud C, Benjannet S, Wickham L, Erlich D, Derré A, Villéger L, Farnier M, Beucler I, Bruckert E, Chambaz J, Chanu B, Lecerf JM, Luc G, Moulin P, Weissenbach J, Prat A, Krempf M, Junien C, Seidah NG, Boileau C: Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003, 34 (2): 154-156.
18. Cariou B, Ouguerram K, Zair Y, Guerois R, Langhi C, Kourimate S, Benoit I, Le May C, Gayet C, Belabbas K, Dufernez F, Chétiveaux M, Tarugi P, Krempf M, Benlian P, Costet P: PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia. Arterioscler Thromb Vasc Biol. 2009, 29 (12): 2191-2197.
19. Benn M, Nordestgaard BG, Grande P, Schnohr P, Tybjaerg-Hansen A: PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses. J Am Coll Cardiol. 2010, 55 (25): 2833-2842.
20. Huijgen R, Fouchier SW, Denoun M, Hutten BA, Vissers MN, Lambert G, Kastelein JJ: Plasma levels of PCSK9 and phenotypic variability in familial hypercholesterolemia. J Lipid Res. 2012, 53 (5): 979-983.
21. Li S, Guo YL, Xu RX, Zhang Y, Zhu CG, Sun J, Qing P, Wu NQ, Jiang LX, Li JJ: Association of plasma PCSK9 levels with white blood cell count and its subsets in patients with stable coronary artery disease. Atherosclerosis. 2014, 234 (2): 441-445.
22. Alborn WE, Cao G, Careskey HE, Qian YW, Subramaniam DR, Davies J, Conner EM, Konrad RJ: Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol. Clin Chem. 2007, 53 (10): 1814-1819.
23. Welder G, Zineh I, Pacanowski MA, Troutt JS, Cao G, Konrad RJ: High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. J Lipid Res. 2010, 51 (9): 2714-2721.
24. Araki S, Suga S, Miyake F, Ichikawa S, Kinjo T, Yamamoto Y, Kusuhara K: Circulating PCSK9 levels correlate with the serum LDL cholesterol level in newborn infants. Early Hum Dev. 2014, 90 (10): 607-611.
25. Kwakernaak AJ, Lambert G, Dullaart RP: Plasma proprotein convertase subtilisin-kexin type 9 is predominantly related to intermediate density lipoproteins. Clin Biochem. 2014, 47 (7-8): 679-682.
26. Werner C, Hoffmann MM, Winkler K, Bohm M, Laufs U: Risk prediction with proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment. Vasc Pharmacol. 2014, 62 (2): 94-102. 10.1016/j.vph.2014.03.004.
27. Mayne J, Raymond A, Chaplin A, Cousins M, Kaefer N, Gyamera-Acheampong C, Seidah NG, Mbikay M, Chretien M, Ooi TC: Plasma PCSK9 levels correlate with cholesterol in men but not in women. Biochem Biophys Res Commun. 2007, 361 (2): 451-456.
28. Smith PM, Cowan A, White BA: The low-density lipoprotein receptor is regulated by estrogen and forms a functional complex with the estrogen-regulated protein ezrin in pituitary GH3 somatolactotropes. Endocrinology. 2004, 145 (7): 3075-3083.
29. Croston GE, Milan LB, Marschke KB, Reichman M, Briggs MR: Androgen receptor-mediated antagonism of estrogen-dependent low density lipoprotein receptor transcription in cultured hepatocytes. Endocrinology. 1997, 138 (9): 3779-3786.
30. Moon JY, Kwon HM, Kwon SW, Yoon SJ, Kim JS, Lee SJ, Park JK, Rhee JH, Yoon YW, Hong BK, Rim SJ, Kim HS: Lipoprotein(a) and LDL particle size are related to the severity of coronary artery disease. Cardiology. 2007, 108 (4): 282-289.
31. Lorincz H, Katkó M, Harangi M, Somodi S, Gaál K, Fülöp P, Paragh G, Seres I: Strong correlations between circulating chemerin levels and lipoprotein subfractions in nondiabetic obese and nonobese subjects. Clin Endocrinol. 2013, 81 (3): 370-377.
32. Srisawasdi P, Vanavanan S, Rochanawutanon M, Pornsuriyasak P, Tantrakul V, Kruthkul K, Kotani K: Heterogeneous properties of intermediate- and low-density lipoprotein subpopulations. Clin Biochem. 2013, 46 (15): 1509-1515.
33. Gentile M, Panico S, Jossa F, Mattiello A, Ubaldi S, Marotta G, Pauciullo P, Rubba P: Small dense LDL particles and metabolic syndrome in a sample of middle-aged women, Findings from Progetto Atena. Clin Chim Acta. 2008, 388 (1-2): 179-183.
34. Williams PT, Zhao XQ, Marcovina SM, Brown BG, Krauss RM: Levels of cholesterol in small LDL particles predict atherosclerosis progression and incident CHD in the HDL-Atherosclerosis Treatment Study (HATS). PLoS One. 2013, 8 (2): e56782-
35. Arsenault BJ, Pelletier-Beaumont E, Almeras N, Tremblay A, Poirier P, Bergeron J, Despres JP: PCSK9 levels in abdominally obese men: Association with cardiometabolic risk profile and effects of a one-year lifestyle modification program. Atherosclerosis. 2014, 236 (2): 321-326.
36. Graham MJ, Lemonidis KM, Whipple CP, Subramaniam A, Monia BP, Crooke ST, Crooke RM: Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice. J Lipid Res. 2007, 48 (4): 763-767.
37. Chan JC, Piper DE, Cao Q, Liu D, King C, Wang W, Tang J, Liu Q, Higbee J, Xia Z, Di Y, Shetterly S, Arimura Z, Salomonis H, Romanow WG, Thibault ST, Zhang R, Cao P, Yang XP, Yu T, Lu M, Retter MW, Kwon G, Henne K, Pan O, Tsai MM, Fuchslocher B, Yang E, Zhou L, Lee KJ: A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc Natl Acad Sci U S A. 2009, 106 (24): 9820-9825.
38. Shaw LJ, Bairey Merz CN, Pepine CJ, Reis SE, Bittner V, Kelsey SF, Olson M, Johnson BD, Mankad S, Sharaf BL, Rogers WJ, Wessel TR, Arant CB, Pohost GM, Lerman A, Quyyumi AA, Sopko G,: Insights from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: Part I: gender differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategies. J Am Coll Cardiol. 2006, 47 (3 Suppl): S4-S20.
39. Dey S, Flather MD, Devlin G, Brieger D, Gurfinkel EP, Steg PG, Fitzgerald G, Jackson EA, Eagle KA,: Sex-related differences in the presentation, treatment and outcomes among patients with acute coronary syndromes: the Global Registry of Acute Coronary Events. Heart. 2009, 95 (1): 20-26.
40. Frink RJ: Gender gap, inflammation and acute coronary disease: are women resistant to atheroma growth? Observations at autopsy. J Invasive Cardiol. 2009, 21 (6): 270-277.
41. Park JS, Kim YJ, Shin DG, Jeong MH, Ahn YK, Chung WS, Seung KB, Kim CJ, Cho MC, Jang YS, Park SJ, Seong IW, Chae SC, Hur SH, Choi DH, Hong TJ, Korean Acute Myocardial Infarction Registry (KAMIR) Group: Gender differences in clinical features and in-hospital outcomes in ST-segment elevation acute myocardial infarction: from the Korean Acute Myocardial Infarction Registry (KAMIR) study. Clin Cardiol. 2010, 33 (8): E1-E6. 10.1002/clc.20557.
42. Chen CH, Jiang T, Yang JH, Jiang W, Lu J, Marathe GK, Pownall HJ, Ballantyne CM, McIntyre TM, Henry PD, Yang CY: Low-density lipoprotein in hypercholesterolemic human plasma induces vascular endothelial cell apoptosis by inhibiting fibroblast growth factor 2 transcription. Circulation. 2003, 107 (16): 2102-2108.
43. Lee AS, Chen WY, Chan HC, Hsu JF, Shen MY, Chang CM, Bair H, Su MJ, Chang KC, Chen CH: Gender disparity in LDL-induced cardiovascular damage and the protective role of estrogens against electronegative LDL. Cardiovasc Diabetol. 2014, 13: 64-
44. Sone H, Takahashi A, Shimano H, Ishibashi S, Yoshino G, Morisaki N, Saito Y, Kawazu S, Teramoto T, Fujita T, Shiba T, Iwamoto Y, Kuzuya N, Akanuma Y, Yamada N: HMG-CoA reductase inhibitor decreases small dense low-density lipoprotein and remnant-like particle cholesterol in patients with type-2 diabetes. Life Sci. 2002, 71 (20): 2403-2412.
45. Evans D, Beil FU: The E670G SNP in the PCSK9 gene is associated with polygenic hypercholesterolemia in men but not in women. BMC Med Genet. 2006, 7: 66-